Defunct Company
Total Trials
9
As Lead Sponsor
6
As Collaborator
3
Total Enrollment
444
NCT01308762
A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
Phase: Phase 1
Role: Lead Sponsor
Start: Mar 31, 2010
Completion: Sep 30, 2010
NCT01303172
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Phase: Phase 2
Start: Jun 30, 2011
Completion: Jan 31, 2016
NCT01559818
A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001
Phase: Phase 1/2
Start: Feb 29, 2012
Completion: Jul 31, 2019
NCT01539824
A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer
Start: May 30, 2012
Completion: Mar 27, 2014
NCT03009058
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
Start: May 31, 2017
Completion: Aug 30, 2017
NCT03711188
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma
Start: Oct 4, 2018
Completion: Dec 2, 2021
NCT04442048
Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure
Phase: Phase 3
Role: Collaborator
Start: Oct 1, 2020
Completion: Dec 31, 2025
NCT05118724
Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin
Start: Dec 10, 2021
Completion: Apr 30, 2027